Clinical Trial Update: A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT) [Phase 3]

View source ↗

Summary

Phase 3 trial of intravesical apaziquone as a surgical adjuvant in TURBT for bladder cancer was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Apaziquone (apaziquone)

Snippet

Sponsor: Spectrum Pharmaceuticals, Inc | Conditions: Bladder Cancer | Phase 3 | Status: TERMINATED | Results posted: 2021-09-27